In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions
View Patent ↗Disclosed are in vitro methods for evaluating the in vivo redispersibility of dosage forms of poorly water-soluble active agents. The methods utilize media representative of in vivo human physiological conditions.
1. An in vitro method for evaluating a solid dosage form, comprising:
(a) dispersing a dosage form in a biorelevant medium, wherein the dosage form comprises at least one poorly water-soluble active agent, and wherein prior to incorporation into the solid dosage form, the active agent has an effective average particle size of greater than 2 microns;
(b) measuring the particle size of the dispersed poorly water-soluble active agent; and
(c) determining if the level of dispersibility is sufficient for in vivo effectiveness of the dosage form, wherein the level of dispersibility is sufficient for in vivo effectiveness of the dosage form if the dosage form disperses such that the particle size of the dispersed active agent particles resembles the particle size of the active agent prior to incorporation into the solid dosage form.
2. The method of claim 1 , wherein the dosage form is selected from the group consisting of solid dosage forms, liquid dosage forms, semi-liquid dosage forms, dry powders, multiparticulates, sprinkles, tablets, capsules, lyophilized formulations, sachets, lozenges, syrups, liquids for injection, and liquids for oral delivery.
3. The method of claim 1 , wherein the dosage form is selected from the group consisting of dosage forms intended for oral, pulmonary, nasal, parenteral, rectal, local, and buccal delivery.
4. The method of claim 1 , wherein prior to incorporation into the dosage form the active agent has an effective average particle size selected from the group consisting of greater than 5 microns, greater than 10 microns, greater than 15 microns, and greater than 20 microns.
5. The method of claim 1 , wherein the biorelevant aqueous media is selected from the group consisting of electrolyte solutions of strong acids, strong bases, weak acids, weak bases, and salts thereof, and mixtures of strong acids, strong bases, weak acids, weak bases, and salts thereof.
6. The method of claim 5 , wherein the electrolyte solution is selected from the group consisting of an HCl solution having a concentration from about 0.001 to about 0.1 M, an NaCl solution having a concentration from about 0.001 to about 0.2 M, and mixtures thereof.
7. The method of claim 5 , wherein the electrolyte solution is selected from the group consisting of about 0.1 M HCl or less, about 0.01 M HCl or less, about 0.001 M HCl or less, about 0.2 M NaCl or less, about 0.001 M NaCl or less, about 0.001 M NaCl or less, and mixtures thereof.
8. The method of claim 5 , wherein the electrolyte solution is selected from the group consisting of 0.01 M HCl and 0.1 M NaCl.
9. The method of claim 1 , wherein the at least one active agent is selected from the group consisting of COX-2 inhibitors, anticancer agents, NSAIDS, proteins, peptides, nutraceuticals, anti-obesity agents, corticosteroids, elastase inhibitors, analgesics, anti-fungals, oncology therapies, anti-emetics, analgesics, cardiovascular agents, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics, anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytics, sedatives, astringents, beta-adrenoceptor blocking agents, cardiac inotropic agents, contrast media, cough suppressants, diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics, haemostatics, immunological agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones, anti-allergic agents, stimulants and anoretics, sympathomimetics, thyroid agents, vasodilators, xanthines, and acne medication.
10. The method of claim 1 , wherein prior to incorporation into the dosage form the active agent has an effective average particle size selected from the group consisting of about 5 microns, about 10 microns, about 15 microns, and about 20 microns.
11. An in vitro method for evaluating a solid dosage form, comprising:
(a) dispersing a dosage form in a biorelevant medium, wherein the dosage form comprises at least one poorly water-soluble active agent, and wherein prior to incorporation into the solid dosage form, the active agent has an effective average particle size of about 2 microns;
(b) measuring the particle size of the dispersed poorly water-soluble active agent; and
(c) determining if the level of dispersibility is sufficient for in vivo effectiveness of the dosage form, wherein the level of dispersibility is sufficient for in vivo effectiveness of the dosage form if the dosage form disperses such that the particle size of the dispersed active agent particles resembles the particle size of the active agent prior to incorporation into the solid dosage form.
12. The method of claim 11 , wherein the dosage form is selected from the group consisting of solid dosage forms, liquid dosage forms, semi-liquid dosage forms, dry powders, multiparticulates, sprinkles, tablets, capsules, lyophilized formulations, sachets, lozenges, syrups, liquids for injection, and liquids for oral delivery.
13. The method of claim 11 , wherein the dosage form is selected from the group consisting of dosage forms intended for oral, pulmonary, nasal, parenteral, rectal, local, and buccal delivery.
14. The method of claim 11 , wherein the biorelevant aqueous media is selected from the group consisting of electrolyte solutions of strong acids, strong bases, weak acids, weak bases, and salts thereof, and mixtures of strong acids, strong bases, weak acids, weak bases, and salts thereof.
15. The method of claim 14 , wherein the electrolyte solution is selected from the group consisting of an HCl solution having a concentration from about 0.001 to about 0.1 M, an NaCl solution having a concentration from about 0.001 to about 0.2 M, and mixtures thereof.
16. The method of claim 14 , wherein the electrolyte solution is selected from the group consisting of about 0.1 M HCl or less, about 0.01 M HCl or less, about 0.001 M HCl or less, about 0.2 M NaCl or less, about 0.01 M NaCl or less, about 0.001 M NaCl or less, and mixtures thereof.
17. The method of claim 14 , wherein the electrolyte solution is selected from the group consisting of 0.01 M HCl and 0.1 M NaCl.
18. The method of claim 11 , wherein the at least one active agent is selected from the group consisting of COX-2 inhibitors, anticancer agents, NSAIDS, proteins, peptides, nutraceuticals, anti-obesity agents, corticosteroids, elastase inhibitors, analgesics, anti-fungals, oncology therapies, anti-emetics, analgesics, cardiovascular agents, anti-inflammatory agents, anthelmintics, anti-arrhythmic agents, antibiotics, anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytics, sedatives, astringents, beta-adrenoceptor blocking agents, cardiac inotropic agents, contrast media, cough suppressants, diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics, haemostatics, immunological agents, lipid regulating agents, muscle relaxants, parasympathomimetics, parathyroid calcitonin and biphosphonates, prostaglandins, radio-pharmaceuticals, sex hormones, anti-allergic agents, stimulants and anoretics, sympathomimetics, thyroid agents, vasodilators, xanthines, and acne medication.